OBJECTIVE:Exhaled nitric oxide (FE(NO)) was evaluated in children with asthma after 4 to 6 years of treatment withbudesonide, nedocromil, or albuterol as needed. STUDY DESIGN: FE(NO), spirometry, total eosinophil count, and serum eosinophil cationic protein levels were obtained from 118 children at the Denver site of the Childhood Asthma Management Program upon completion of treatment and after a 2- to 4-month washout. RESULTS:Budesonide-treated patients had significantly lower median (1st, 3rd quartile) FE(NO) (21.5 [13.2, 84.4] vs 62.5 [26.2, 115.0] ppb, P <.01) and eosinophil cationic protein levels (17.4 [10.1, 24.3] vs 24.0 [15.4, 33.9] mg/dL, P =.05) compared with placebo, whereas no differences were noted between nedocromil and placebo groups. After washout, FE(NO) levels were similar between the three treatments. FE(NO) levels significantly correlated with degree of bronchial hyperresponsiveness, bronchodilator reversibility, allergen skin prick tests, serum IgE, and total eosinophil count. FE(NO) levels were also higher in patients with nocturnal symptoms and in patients requiring beta-agonist use at least once weekly. CONCLUSIONS:Budesonide therapy was more effective than nedocromil in reducing FE(NO). Unfortunately, the effects of long-term budesonide were not sustained after its discontinuation. FE(NO) may be a complementary tool to current practice guidelines in assessing asthma control and medication response.
RCT Entities:
OBJECTIVE: Exhaled nitric oxide (FE(NO)) was evaluated in children with asthma after 4 to 6 years of treatment with budesonide, nedocromil, or albuterol as needed. STUDY DESIGN:FE(NO), spirometry, total eosinophil count, and serum eosinophil cationic protein levels were obtained from 118 children at the Denver site of the Childhood Asthma Management Program upon completion of treatment and after a 2- to 4-month washout. RESULTS:Budesonide-treated patients had significantly lower median (1st, 3rd quartile) FE(NO) (21.5 [13.2, 84.4] vs 62.5 [26.2, 115.0] ppb, P <.01) and eosinophil cationic protein levels (17.4 [10.1, 24.3] vs 24.0 [15.4, 33.9] mg/dL, P =.05) compared with placebo, whereas no differences were noted between nedocromil and placebo groups. After washout, FE(NO) levels were similar between the three treatments. FE(NO) levels significantly correlated with degree of bronchial hyperresponsiveness, bronchodilator reversibility, allergen skin prick tests, serum IgE, and total eosinophil count. FE(NO) levels were also higher in patients with nocturnal symptoms and in patients requiring beta-agonist use at least once weekly. CONCLUSIONS:Budesonide therapy was more effective than nedocromil in reducing FE(NO). Unfortunately, the effects of long-term budesonide were not sustained after its discontinuation. FE(NO) may be a complementary tool to current practice guidelines in assessing asthma control and medication response.
Authors: Adam J Spanier; Robert S Kahn; Richard Hornung; Michelle Lierl; Bruce P Lanphear Journal: Pediatr Allergy Immunol Pulmonol Date: 2011-03 Impact factor: 1.349
Authors: Stanley J Szefler; Herman Mitchell; Christine A Sorkness; Peter J Gergen; George T O'Connor; Wayne J Morgan; Meyer Kattan; Jacqueline A Pongracic; Stephen J Teach; Gordon R Bloomberg; Peyton A Eggleston; Rebecca S Gruchalla; Carolyn M Kercsmar; Andrew H Liu; Jeremy J Wildfire; Matthew D Curry; William W Busse Journal: Lancet Date: 2008-09-20 Impact factor: 79.321
Authors: Stanley P Galant; Tricia Morphew; Robert L Newcomb; Kiem Hioe; Olga Guijon; Otto Liao Journal: J Pediatr Date: 2011-01-13 Impact factor: 4.406
Authors: Nathan Rabinovitch; Nora J Graber; Vernon M Chinchilli; Christine A Sorkness; Robert S Zeiger; Robert C Strunk; Leonard B Bacharier; Fernando D Martinez; Stanley J Szefler Journal: J Allergy Clin Immunol Date: 2010-09 Impact factor: 10.793
Authors: Rebecca S Gruchalla; Hugh A Sampson; Elizabeth Matsui; Gloria David; Peter J Gergen; Agustin Calatroni; Mark Brown; Andrew H Liu; Gordon R Bloomberg; James F Chmiel; Rajesh Kumar; Carin Lamm; Ernestine Smartt; Christine A Sorkness; Suzanne F Steinbach; Kelly D Stone; Stanley J Szefler; William W Busse Journal: J Allergy Clin Immunol Date: 2009-07-16 Impact factor: 10.793
Authors: Avraham Beigelman; David T Mauger; Brenda R Phillips; Robert S Zeiger; Lynn M Taussig; Robert C Strunk; Leonard B Bacharier Journal: Ann Allergy Asthma Immunol Date: 2009-08 Impact factor: 6.347